STOCK TITAN
  1. Home
  2. News
  3. IMNM

Immunome Inc - IMNM STOCK NEWS

Welcome to our dedicated news page for Immunome (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immunome's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immunome's position in the market.

News
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
Rhea-AI Summary
Immunome, Inc. (IMNM) announces the presentation of preclinical data for IM-3050, a lead lutetium-177 radioligand therapy targeting fibroblast activation protein (FAP) at the AACR Annual Meeting 2024. The company aims to develop novel cancer therapies with improved therapeutic properties, expecting to submit an Investigational New Drug application in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
-
News
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
Rhea-AI Summary
Immunome, Inc. (IMNM) announces transformative year with merger, pipeline advancements, and financial results for 2023. Key highlights include the acquisition of assets, successful financing, and progress in developing targeted cancer therapies. Topline data for Phase 3 RINGSIDE trial of AL102 expected in Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.41%
Tags
acquisition earnings
-
News
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
Rhea-AI Summary
Immunome, Inc. (IMNM) completes the acquisition of AL102 and AL101 from Ayala Pharmaceuticals, focusing on targeted cancer therapies. AL102, a gamma secretase inhibitor, shows promise in treating desmoid tumors, potentially setting a new standard of care. Immunome aims to advance AL102 towards Phase 1 trials, emphasizing its potential efficacy over OGSIVEO™.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.79%
Tags
acquisition clinical trial
News
Arrayjet’s ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies
Rhea-AI Summary
Arrayjet partners with Immunome, Inc. (IMNM) to provide its ArrayPlex™ discovery platform for high-throughput screening of targeted cancer therapies. Arrayjet's inkjet technology enables rapid multi-layered assays with two-million data points per cycle, enhancing the discovery of unique binding interactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
none
-
News
Immunome to Participate in the Leerink Partners Global Biopharma Conference
Rhea-AI Summary
Immunome, Inc. (IMNM) announces Clay Siegall, Ph.D., will present at Leerink Partners 2024 Global Biopharma Conference. The focus is on developing targeted cancer therapies. The presentation will be available via live audio webcast on March 12, 2024, at 4:20 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.8%
Tags
conferences
-
News
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
Rhea-AI Summary
Immunome, Inc. (IMNM) announced the participation of its President and CEO in a targeted oncology panel at the TD Cowen 44th Annual Health Care Conference. The live webcast can be accessed on the company's website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
conferences
News
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
Rhea-AI Summary
Immunome, Inc. (IMNM) has entered into an asset purchase agreement with Ayala Pharmaceuticals to acquire AL102 and related drug candidate AL101. Ayala has completed patient enrollment in the Phase 3 RINGSIDE study for AL102 in desmoid tumors. Immunome's Chief Medical Officer is optimistic about the trial's progress and potential, with plans to finalize the acquisition in the coming months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.99%
Tags
clinical trial
-
News
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Rhea-AI Summary
Immunome, Inc. (IMNM) successfully closed a public offering, raising $230.0 million by selling 10,000,000 shares of common stock at $20.00 per share. The underwriters also exercised their option to purchase an additional 1,500,000 shares. The offering was managed by J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities. Immunome plans to utilize the proceeds for developing targeted cancer therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
News
Immunome Announces Pricing of Public Offering of Common Stock
Rhea-AI Summary
Immunome, Inc. (IMNM) announces the pricing of an underwritten public offering of 10,000,000 shares of its common stock at $20.00 per share, expecting to raise $200.0 million. The offering includes a 30-day option for additional shares. The offering is set to close on February 16, 2024, with J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities as joint book-running managers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
offering
News
Immunome Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
Immunome, Inc. (IMNM) announces plans for a $200.0 million public offering of common stock for cancer therapies development. Underwritten by J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities, the offering includes a 30-day option for additional shares. The offering is based on a shelf registration statement filed with the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
offering
Stock IMNM logo
Immunome Inc

Nasdaq:IMNM

IMNM Rankings

#2527 Ranked by Market Cap
#137 Ranked by Stock Gains
N/A Ranked by Dividends

IMNM Stock Data

1.23B
44.03M
18.1%
37.51%
5.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Bothell

About IMNM

immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. this proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. we then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.